RDS
MCID: RSP019
MIFTS: 58

Respiratory Distress Syndrome in Premature Infants (RDS)

Categories: Rare diseases, Respiratory diseases

Aliases & Classifications for Respiratory Distress Syndrome in Premature Infants

MalaCards integrated aliases for Respiratory Distress Syndrome in Premature Infants:

Name: Respiratory Distress Syndrome in Premature Infants 56 73 29
Hyaline Membrane Disease 58 73 54 71
Neonatal Respiratory Distress 29 6
Infant Acute Respiratory Distress Syndrome 58
Neonatal Respiratory Distress Syndrome 58
Respiratory Distress Syndrome, Newborn 71
Infant Respiratory Distress Syndrome 58
Hyaline Membrane Disease, Formerly 56
Rds of Prematurity 56
Rds in Prematurity 73
Infant Ards 58
Rds 73

Characteristics:

Orphanet epidemiological data:

58
infant acute respiratory distress syndrome
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Infancy,Neonatal;

OMIM:

56
Inheritance:
isolated cases
multifactorial

Miscellaneous:
onset at birth
may be associated with polymorphisms in some surfactant genes, including sftpa1 , sftpb , and sftpc


HPO:

31
respiratory distress syndrome in premature infants:
Inheritance multifactorial inheritance sporadic
Onset and clinical course congenital onset


Classifications:

Orphanet: 58  
Rare respiratory diseases


External Ids:

OMIM 56 267450
MeSH 43 D006819
ICD10 via Orphanet 33 P22.0
UMLS via Orphanet 72 C0020192 C0035220 C0852283
Orphanet 58 ORPHA70587
MedGen 41 C1968593
UMLS 71 C0020192 C0035220

Summaries for Respiratory Distress Syndrome in Premature Infants

OMIM : 56 The main cause of respiratory distress syndrome (RDS) in premature infants is a developmental deficiency of pulmonary surfactant. The frequency of RDS is inversely proportional to gestational age. However, not all infants born prematurely develop RDS, suggesting that there may be susceptibility factors. Because multiple factors can contribute to the pathogenesis of RDS specifically in premature infants, the etiology is considered to be multifactorial (summaries by Ramet et al., 2000; Clark and Clark, 2005). Pathogenic germline mutations in several genes involved in surfactant metabolism, including SFTPB (178640) and SFTPC (178620), can cause clinical features of respiratory distress syndrome in term neonates, children, and adults, disorders referred to as 'surfactant metabolism dysfunction' (see, e.g., SMDP1, 265120). Susceptibility to the development of RDS in premature infants may be associated with polymorphisms in surfactant genes, such as surfactant protein A1 (SFTPA1; 178630), SFTPB, and SFTPC (see MOLECULAR GENETICS). (267450)

MalaCards based summary : Respiratory Distress Syndrome in Premature Infants, also known as hyaline membrane disease, is related to adult respiratory distress syndrome and pulmonary alveolar proteinosis, and has symptoms including dyspnea, hemoptysis and apnea. An important gene associated with Respiratory Distress Syndrome in Premature Infants is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are HIV Life Cycle and Diseases of metabolism. The drugs Epinephrine and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include lung, fetal lung and testes, and related phenotypes are atelectasis and premature birth

UniProtKB/Swiss-Prot : 73 Respiratory distress syndrome in premature infants: A lung disease affecting usually premature newborn infants. It is characterized by deficient gas exchange, diffuse atelectasis, high- permeability lung edema and fibrin-rich alveolar deposits called 'hyaline membranes'.

Wikipedia : 74 Infantile respiratory distress syndrome (IRDS), also called respiratory distress syndrome of newborn, or... more...

Related Diseases for Respiratory Distress Syndrome in Premature Infants

Diseases related to Respiratory Distress Syndrome in Premature Infants via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 461, show less)
# Related Disease Score Top Affiliating Genes
1 adult respiratory distress syndrome 29.7 SFTPC SFTPB
2 pulmonary alveolar proteinosis 29.7 SFTPC SFTPB SFTPA1
3 interstitial emphysema 29.4 SFTPC SFTPB SFTPA1 ABCA3
4 surfactant dysfunction 29.2 SFTPC SFTPB SFTPA1 ABCA3
5 pulmonary immaturity 29.1 SFTPC SFTPB SFTPA1 ABCA3
6 respiratory failure 28.9 SFTPC SFTPB NKX2-1 ABCA3
7 diaphragmatic hernia, congenital 28.5 SFTPC SFTPB NKX2-1 GRP
8 neonatal respiratory failure 28.5 SFTPC SFTPB NKX2-1 ABCA3
9 newborn respiratory distress syndrome 28.0 SFTPC SFTPB SFTPA1 NKX2-1 GRP ABCA3
10 lung disease 27.9 SFTPC SFTPB SFTPA1 NKX2-1 GRP ABCA3
11 choreoathetosis and congenital hypothyroidism with or without pulmonary dysfunction 12.1
12 restrictive dermopathy, lethal 12.0
13 reticular dysgenesis 12.0
14 respiratory distress syndrome, infant 11.9
15 refsum disease, classic 11.9
16 radin blood group antigen 11.7
17 kartagener syndrome 11.6
18 choroidal dystrophy, central areolar, 1 11.5
19 ciliary dyskinesia, primary, 26 11.4
20 ciliary dyskinesia, primary, 27 11.4
21 ciliary dyskinesia, primary, 9 11.3
22 ciliary dyskinesia, primary, 38 11.3
23 neurodevelopmental disorder with hypotonia, neonatal respiratory insufficiency, and thermodysregulation 11.3
24 renal hypodysplasia/aplasia 1 11.2
25 renal hypodysplasia/aplasia 2 11.2
26 retinal degeneration 10.9
27 retinitis pigmentosa 10.8
28 neuroretinitis 10.8
29 retinitis 10.8
30 haemophilus influenzae 10.7
31 rhabdomyosarcoma 10.6
32 bronchopulmonary dysplasia 10.5
33 retinal disease 10.5
34 macular degeneration, age-related, 1 10.4
35 pneumothorax 10.4
36 yemenite deaf-blind hypopigmentation syndrome 10.4
37 pattern dystrophy 10.4
38 fundus dystrophy 10.3
39 inherited retinal disorder 10.3
40 patent ductus arteriosus 1 10.3
41 macular dystrophy, patterned, 1 10.3
42 retinitis pigmentosa 7 10.3
43 butterfly-shaped pigment dystrophy 10.3
44 situs inversus 10.2
45 cerebral artery occlusion 10.2
46 choroidal dystrophy, central areolar 2 10.2
47 alcohol dependence 10.2
48 ischemia 10.2
49 pre-eclampsia 10.2
50 cone-rod dystrophy 2 10.2
51 retinal detachment 10.2
52 macular dystrophy, vitelliform, 3 10.2
53 teratoma 10.2
54 gestational diabetes 10.1
55 disseminated intravascular coagulation 10.1
56 pulmonary edema 10.1
57 attention deficit-hyperactivity disorder 10.1
58 vitelliform macular dystrophy 10.1
59 ventilation pneumonitis 10.1 SFTPB ABCA3
60 surfactant metabolism dysfunction, pulmonary, 1 10.1 SFTPB ABCA3
61 lipid pneumonia 10.1 SFTPB ABCA3
62 dacryocystocele 10.1
63 cystic adenomatoid malformation of lung 10.1
64 myeloma, multiple 10.1
65 pulmonary hemosiderosis 10.1 SFTPB ABCA3
66 enterocolitis 10.1
67 pneumonia 10.1
68 perinatal necrotizing enterocolitis 10.1
69 otitis media 10.0
70 preterm premature rupture of the membranes 10.0
71 funisitis 10.0
72 intrahepatic cholestasis of pregnancy 10.0
73 cerebral palsy 10.0
74 cervical incompetence 10.0
75 fundus albipunctatus 10.0
76 helix syndrome 10.0
77 night blindness 10.0
78 soft tissue sarcoma 10.0
79 chronic congestive splenomegaly 10.0 SFTPC ABCA3
80 exudative vitreoretinopathy 1 10.0
81 cardiac arrest 10.0
82 periventricular leukomalacia 10.0
83 congestive heart failure 10.0
84 emphysema, congenital lobar 10.0
85 lacrimal duct defect 10.0
86 congenital heart defects, hamartomas of tongue, and polysyndactyly 10.0
87 mumps 10.0
88 fibrous histiocytoma 10.0
89 dextrocardia 10.0
90 congenital syphilis 10.0
91 dextrocardia with situs inversus 10.0
92 lymphangiectasis 10.0
93 pulmonary hypertension 10.0
94 chorioamnionitis 10.0
95 metabolic acidosis 10.0
96 placenta praevia 10.0
97 asphyxia neonatorum 10.0
98 kernicterus 10.0
99 bacterial pneumonia 10.0
100 placental abruption 10.0
101 cytokine deficiency 10.0
102 hypoxia 10.0
103 colorectal cancer 10.0
104 immune deficiency disease 10.0
105 human immunodeficiency virus type 1 10.0
106 cone dystrophy 10.0
107 colitis 10.0
108 substance abuse 10.0
109 embryonal rhabdomyosarcoma 10.0
110 glioma 10.0
111 monogenic diabetes 10.0
112 glial tumor 10.0
113 lysinuric protein intolerance 10.0 SFTPB ABCA3
114 nonspecific interstitial pneumonia 10.0 SFTPC ABCA3
115 idiopathic interstitial pneumonia 9.9 SFTPC SFTPB SFTPA1
116 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.9
117 leigh syndrome 9.9
118 pyruvate kinase deficiency of red cells 9.9
119 sudden infant death syndrome 9.9
120 allergic rhinitis 9.9
121 antithrombin iii deficiency 9.9
122 cyanosis, transient neonatal 9.9
123 pain agnosia 9.9
124 goiter 9.9
125 diarrhea 9.9
126 rhinitis 9.9
127 b-cell lymphoma 9.9
128 placenta disease 9.9
129 diabetes mellitus 9.9
130 primary ciliary dyskinesia 9.9
131 nkx2-1-related disorders 9.9
132 bronchogenic cyst 9.9
133 neonatal hypoxic and ischemic brain injury 9.9
134 diffuse pulmonary fibrosis 9.9 GRP ABCA3
135 alzheimer disease 9.9
136 atherosclerosis susceptibility 9.9
137 autoimmune disease 9.9
138 hypercarotenemia and vitamin a deficiency, autosomal dominant 9.9
139 macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss 9.9
140 nephrolithiasis, calcium oxalate 9.9
141 retinoblastoma 9.9
142 lung cancer 9.9
143 cystic fibrosis 9.9
144 stargardt disease 1 9.9
145 arts syndrome 9.9
146 taqi polymorphism 9.9
147 cervical cancer 9.9
148 gastric cancer 9.9
149 diffuse large b-cell lymphoma 9.9
150 scoliosis 9.9
151 hand, foot and mouth disease 9.9
152 keratomalacia 9.9
153 peripheral retinal degeneration 9.9
154 bronchopneumonia 9.9
155 dementia 9.9
156 alcohol use disorder 9.9
157 thrombocytopenia 9.9
158 post-traumatic stress disorder 9.9
159 pulmonary tuberculosis 9.9
160 mouth disease 9.9
161 syphilis 9.9
162 familial retinoblastoma 9.9
163 nephrolithiasis 9.9
164 acute stress disorder 9.9
165 end stage renal disease 9.9
166 learning disability 9.9
167 scotoma 9.9
168 drug dependence 9.9
169 nonsyndromic retinitis pigmentosa 9.9
170 allergic encephalomyelitis 9.9
171 rapidly involuting congenital hemangioma 9.9
172 argyria 9.9
173 laryngitis 9.9
174 bronchitis 9.9
175 cleft palate, isolated 9.9
176 laryngomalacia 9.9
177 chondrodysplasia punctata syndrome 9.9
178 ciliary dyskinesia, primary, 1 9.9
179 pierre robin syndrome 9.9
180 pulmonary hypoplasia, primary 9.9
181 mucopolysaccharidosis, type ii 9.9
182 myopathy, centronuclear, x-linked 9.9
183 pelizaeus-merzbacher disease 9.9
184 niemann-pick disease, type c2 9.9
185 bone disease 9.9
186 rickets 9.9
187 hypoparathyroidism 9.9
188 orbital cellulitis 9.9
189 visual epilepsy 9.9
190 secondary hyperparathyroidism of renal origin 9.9
191 secondary hyperparathyroidism 9.9
192 hyperparathyroidism 9.9
193 niemann-pick disease 9.9
194 centronuclear myopathy 9.9
195 lymphangioma 9.9
196 cellulitis 9.9
197 protein c deficiency 9.9
198 myopathy 9.9
199 gastric teratoma 9.9
200 spinal stenosis 9.9
201 peptic ulcer disease 9.9
202 peptic ulcer perforation 9.9
203 peritonitis 9.9
204 polycythemia 9.9
205 allergic asthma 9.9
206 lipid storage disease 9.9
207 dacryoadenitis 9.9
208 bronchiectasis 9.9
209 pathologic nystagmus 9.9
210 dacryocystitis 9.9
211 hypereosinophilic syndrome 9.9
212 myotonic dystrophy 9.9
213 congenital cytomegalovirus 9.9
214 congenital mumps 9.9
215 cor triatriatum 9.9
216 cor triatriatum sinister 9.9
217 encephalocele 9.9
218 tracheal agenesis 9.9
219 isolated pierre robin sequence 9.9
220 hypotonia 9.9
221 seizure disorder 9.9
222 spasticity 9.9
223 nasolacrimal duct cyst 9.9
224 nasopharyngeal teratoma 9.9
225 nasal glial heterotopia 9.9
226 epignathus 9.9
227 congenital laryngeal cyst 9.9
228 neurenteric cyst 9.9
229 rare lymphatic malformation 9.9
230 interstitial pneumonitis, desquamative, familial 9.8 SFTPC SFTPB ABCA3
231 medulloblastoma 9.8
232 tracheoesophageal fistula with or without esophageal atresia 9.8
233 hydrops fetalis, nonimmune 9.8
234 hypertension, early-onset, autosomal dominant, with severe exacerbation in pregnancy 9.8
235 aspiration pneumonia 9.8
236 congenital hypothyroidism 9.8
237 polycystic kidney disease 9.8
238 bacterial infectious disease 9.8
239 esophageal atresia 9.8
240 meconium aspiration syndrome 9.8
241 severe pre-eclampsia 9.8
242 cholestasis 9.8
243 eclampsia 9.8
244 hypothyroidism 9.8
245 hyperinsulinism 9.8
246 neonatal jaundice 9.8
247 bronchiolitis 9.8
248 placental insufficiency 9.8
249 kidney disease 9.8
250 compartment syndrome 9.8
251 chickenpox 9.8
252 encephalitis 9.8
253 47,xyy 9.8
254 48,xyyy 9.8
255 mycetoma 9.8
256 pulmonary sequestration 9.8
257 cytomegalovirus infection 9.8
258 multicystic dysplastic kidney 9.8
259 acute interstitial pneumonia 9.8 SFTPC SFTPB ABCA3
260 alveoli adenoma 9.8 SFTPC NKX2-1
261 pulmonary fibrosis 9.8 SFTPC SFTPA1 ABCA3
262 bronchial benign neoplasm 9.8 SFTPC NKX2-1
263 thyroid carcinoma 9.8 NKX2-1 BRAF
264 pulmonary sclerosing hemangioma 9.8 SFTPB NKX2-1
265 tall cell variant papillary carcinoma 9.8 NKX2-1 BRAF
266 lung carcinoma in situ 9.8 SFTPC NKX2-1
267 sclerosing hemangioma 9.8 SFTPB NKX2-1
268 pulmonary adenocarcinoma in situ 9.8 SFTPC NKX2-1
269 papillary adenoma 9.8 SFTPC NKX2-1
270 papillary thyroid microcarcinoma 9.8 NKX2-1 BRAF
271 peritoneal serous adenocarcinoma 9.8 SFTPC NKX2-1
272 gastroesophageal reflux 9.7
273 burkitt lymphoma 9.7
274 breast cancer 9.7
275 hepatocellular carcinoma 9.7
276 hair whorl 9.7
277 macular dystrophy, vitelliform, 2 9.7
278 acrofacial dysostosis 1, nager type 9.7
279 treacher collins syndrome 1 9.7
280 parkinson disease, late-onset 9.7
281 pheochromocytoma 9.7
282 pick disease of brain 9.7
283 prader-willi syndrome 9.7
284 pulmonary hypertension, primary, 1 9.7
285 dowling-degos disease 1 9.7
286 schistosoma mansoni infection, susceptibility/ 9.7
287 small cell cancer of the lung 9.7
288 neural tube defects 9.7
289 thrombophilia due to thrombin defect 9.7
290 tobacco addiction 9.7
291 triiodothyronine receptor auxiliary protein 9.7
292 vitreoretinopathy, neovascular inflammatory 9.7
293 acheiropody 9.7
294 ataxia-telangiectasia 9.7
295 leukoencephalopathy, hereditary diffuse, with spheroids 9.7
296 lymphoma, hodgkin, classic 9.7
297 nijmegen breakage syndrome 9.7
298 ocular motor apraxia 9.7
299 3-methylglutaconic aciduria, type iii 9.7
300 polycystic kidney disease 4 with or without polycystic liver disease 9.7
301 enhanced s-cone syndrome 9.7
302 rhabdomyosarcoma 2 9.7
303 squamous cell carcinoma, head and neck 9.7
304 retinitis pigmentosa 3 9.7
305 fragile x syndrome 9.7
306 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 9.7
307 choroideremia 9.7
308 muscular dystrophy, duchenne type 9.7
309 norrie disease 9.7
310 retinoschisis 1, x-linked, juvenile 9.7
311 rett syndrome 9.7
312 ataxia and polyneuropathy, adult-onset 9.7
313 kearns-sayre syndrome 9.7
314 prostatic hyperplasia, benign 9.7
315 retinitis pigmentosa 12 9.7
316 retinitis pigmentosa 14 9.7
317 cone-rod dystrophy 5 9.7
318 stroke, ischemic 9.7
319 cone dystrophy 3 9.7
320 lymphoma, non-hodgkin, familial 9.7
321 maturity-onset diabetes of the young 9.7
322 body mass index quantitative trait locus 1 9.7
323 pulmonary disease, chronic obstructive 9.7
324 mycobacterium tuberculosis 1 9.7
325 rhabdoid tumor predisposition syndrome 1 9.7
326 hepatitis c virus 9.7
327 retinitis pigmentosa 36 9.7
328 malaria 9.7
329 smoking as a quantitative trait locus 3 9.7
330 muscle hypertrophy 9.7
331 mucopolysaccharidosis-plus syndrome 9.7
332 joint laxity, short stature, and myopia 9.7
333 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 9.7
334 juvenile arthritis 9.7
335 stargardt disease 9.7
336 deficiency anemia 9.7
337 chikungunya 9.7
338 swine influenza 9.7
339 usher syndrome 9.7
340 exanthem 9.7
341 congenital stationary night blindness 9.7
342 inflammatory bowel disease 9.7
343 extrapulmonary tuberculosis 9.7
344 mantle cell lymphoma 9.7
345 adrenal gland pheochromocytoma 9.7
346 sexual disorder 9.7
347 lymphoma 9.7
348 idiopathic scoliosis 9.7
349 acrofacial dysostosis 9.7
350 myh-9 related disease 9.7
351 bone resorption disease 9.7
352 adenoid cystic carcinoma 9.7
353 non-alcoholic fatty liver disease 9.7
354 igg4-related disease 9.7
355 digenic disease 9.7
356 covid-19 9.7
357 leber plus disease 9.7
358 sensorineural hearing loss 9.7
359 osteomyelitis 9.7
360 prostatic hypertrophy 9.7
361 pertussis 9.7
362 chlamydia 9.7
363 scleral staphyloma 9.7
364 myopia 9.7
365 ecthyma 9.7
366 esophagitis 9.7
367 allergic hypersensitivity disease 9.7
368 aseptic meningitis 9.7
369 male infertility 9.7
370 pathological gambling 9.7
371 telangiectasis 9.7
372 ehlers-danlos syndrome 9.7
373 reading disorder 9.7
374 schistosomiasis 9.7
375 peptic esophagitis 9.7
376 geographic tongue 9.7
377 foster-kennedy syndrome 9.7
378 candidiasis 9.7
379 avoidant personality disorder 9.7
380 personality disorder 9.7
381 status epilepticus 9.7
382 impotence 9.7
383 hepatitis c 9.7
384 melanoma 9.7
385 dysostosis 9.7
386 pharyngitis 9.7
387 opiate dependence 9.7
388 epidermolysis bullosa 9.7
389 prostatic adenoma 9.7
390 adenocarcinoma 9.7
391 acute kidney failure 9.7
392 glioblastoma multiforme 9.7
393 oligodendroglioma 9.7
394 central nervous system disease 9.7
395 fibrosarcoma 9.7
396 histiocytosis 9.7
397 multidrug-resistant tuberculosis 9.7
398 skeletal muscle cancer 9.7
399 skeletal muscle neoplasm 9.7
400 muscle cancer 9.7
401 liver disease 9.7
402 systemic scleroderma 9.7
403 brain edema 9.7
404 borna disease 9.7
405 infertility 9.7
406 sleep disorder 9.7
407 eye disease 9.7
408 severe combined immunodeficiency 9.7
409 fibromyalgia 9.7
410 acquired immunodeficiency syndrome 9.7
411 juvenile rheumatoid arthritis 9.7
412 neuroblastoma 9.7
413 cataract 9.7
414 polyhydramnios 9.7
415 hereditary retinal dystrophy 9.7
416 ulcerative colitis 9.7
417 nervous system disease 9.7
418 autosomal dominant polycystic kidney disease 9.7
419 fatty liver disease 9.7
420 bacterial meningitis 9.7
421 meningitis 9.7
422 stomatitis 9.7
423 refractive error 9.7
424 miliary tuberculosis 9.7
425 alopecia 9.7
426 muscular dystrophy 9.7
427 periostitis 9.7
428 hypoglycemia 9.7
429 albinism 9.7
430 best vitelliform macular dystrophy 9.7
431 rpe65-related leber congenital amaurosis / early-onset severe retinal dystrophy 9.7
432 congenital amputation 9.7
433 hemorrhagic shock and encephalopathy syndrome 9.7
434 brain injury 9.7
435 dysphagia 9.7
436 spinal cord injury 9.7
437 syncope 9.7
438 traumatic brain injury 9.7
439 tremor 9.7
440 benign idiopathic neonatal seizures 9.7
441 pik3ca-related overgrowth syndrome 9.7
442 rare dementia 9.7
443 multifocal pattern dystrophy simulating fundus flavimaculatus 9.7
444 fundus pulverulentus 9.7
445 vitreoretinopathy 9.7
446 struma ovarii 9.7 NKX2-1 BRAF
447 respiratory system benign neoplasm 9.7 SFTPC NKX2-1
448 differentiated thyroid carcinoma 9.6 NKX2-1 BRAF
449 follicular adenoma 9.6 NKX2-1 BRAF
450 diaphragm disease 9.6 SFTPC SFTPB NKX2-1
451 thyroiditis 9.6 NKX2-1 BRAF
452 ischiocoxopodopatellar syndrome with or without pulmonary arterial hypertension 9.6 SFTPC SFTPB SFTPA1 ABCA3
453 pulmonary blastoma 9.5 NKX2-1 GRP
454 small cell carcinoma 9.4 NKX2-1 GRP
455 lung benign neoplasm 9.4 SFTPC NKX2-1 GRP
456 thyroid carcinoma, familial medullary 9.3 NKX2-1 GRP BRAF
457 interstitial lung disease 9.2 SFTPC SFTPB NKX2-1 ABCA3
458 neuroendocrine carcinoma 9.2 NKX2-1 GRP
459 large cell carcinoma 9.1 SFTPC SFTPB NKX2-1 GRP
460 pulmonary fibrosis, idiopathic 9.1 SFTPC SFTPB SFTPA1 GRP ABCA3
461 lung cancer susceptibility 3 8.8 SOD2 SFTPC SFTPB NKX2-1 BRAF

Graphical network of the top 20 diseases related to Respiratory Distress Syndrome in Premature Infants:



Diseases related to Respiratory Distress Syndrome in Premature Infants

Symptoms & Phenotypes for Respiratory Distress Syndrome in Premature Infants

Human phenotypes related to Respiratory Distress Syndrome in Premature Infants:

58 31 (showing 19, show less)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 atelectasis 58 31 Frequent (79-30%) HP:0100750
2 premature birth 58 31 Frequent (79-30%) HP:0001622
3 tachypnea 58 31 Frequent (79-30%) HP:0002789
4 pulmonary edema 58 31 Frequent (79-30%) HP:0100598
5 neonatal respiratory distress 31 HP:0002643
6 abnormality of the thorax 58 Frequent (79-30%)
7 sepsis 58 Very rare (<4-1%)
8 respiratory failure 58 Frequent (79-30%)
9 tachycardia 58 Occasional (29-5%)
10 respiratory distress 31 HP:0002098
11 hypoxemia 58 Very frequent (99-80%)
12 pneumonia 58 Occasional (29-5%)
13 hypotension 58 Occasional (29-5%)
14 cyanosis 58 Frequent (79-30%)
15 respiratory tract infection 58 Occasional (29-5%)
16 disseminated intravascular coagulation 31 HP:0005521
17 cardiac arrest 58 Occasional (29-5%)
18 bradycardia 58 Occasional (29-5%)
19 nasal flaring 58 Frequent (79-30%)

Symptoms via clinical synopsis from OMIM:

56
Respiratory:
dyspnea
tachypnea
respiratory insufficiency, neonatal

Prenatal Manifestations Delivery:
premature delivery, less than 37 weeks' gestation

Respiratory Lung:
atelectasis
decreased surfactant
lung edema
fibrin-rich alveolar deposits, 'hyaline membranes'
diffuse reticulogranular pattern seen on chest radiograph

Clinical features from OMIM:

267450

UMLS symptoms related to Respiratory Distress Syndrome in Premature Infants:


dyspnea, hemoptysis, apnea, respiratory distress, cheyne-stokes respiration, coughing, hoarseness

MGI Mouse Phenotypes related to Respiratory Distress Syndrome in Premature Infants:

45 (showing 5, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.87 ABCA3 BRAF GRP NKX2-1 SFTPB SFTPC
2 cardiovascular system MP:0005385 9.73 ABCA3 BRAF GRP NKX2-1 SFTPC SOD2
3 mortality/aging MP:0010768 9.7 ABCA3 BRAF NKX2-1 SFTPA1 SFTPB SFTPC
4 neoplasm MP:0002006 9.26 BRAF NKX2-1 SFTPC SOD2
5 respiratory system MP:0005388 9.17 ABCA3 BRAF GRP NKX2-1 SFTPA1 SFTPB

Drugs & Therapeutics for Respiratory Distress Syndrome in Premature Infants

Drugs for Respiratory Distress Syndrome in Premature Infants (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 294, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
2
Racepinephrine Approved Phase 4 329-65-7 838
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
5
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
6
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
7
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
8
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
9
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
10
Zinc Approved, Investigational Phase 4 7440-66-6 32051
11
Coal tar Approved Phase 4 8007-45-2
12
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
13
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
14
Remifentanil Approved Phase 4 132875-61-7 60815
15
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
16
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
17 Poractant alfa Approved Phase 4 129069-19-8
18 Beractant Approved Phase 4 108778-82-1
19
Budesonide Approved Phase 4 51333-22-3 63006 5281004
20
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
21
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
22
Beta carotene Approved, Nutraceutical Phase 4 7235-40-7
23 Epinephryl borate Phase 4
24 Anesthetics, Inhalation Phase 4
25 BB 1101 Phase 4
26 Excitatory Amino Acid Antagonists Phase 4
27 Anesthetics, Dissociative Phase 4
28 Calciferol Phase 4
29 Angiotensin II Type 1 Receptor Blockers Phase 4
30 Angiotensinogen Phase 4
31 Angiotensin Receptor Antagonists Phase 4
32 Giapreza Phase 4
33 Antihypertensive Agents Phase 4
34 Calcium, Dietary Phase 4
35 Carotenoids Phase 4
36
Picolinic acid Phase 4 98-98-6 1018
37 Provitamins Phase 4
38 Chelating Agents Phase 4
39 Iron Chelating Agents Phase 4
40 Tin Fluorides Phase 4
41
Glycopyrrolate Phase 4 596-51-0 3494
42 Anti-Anxiety Agents Phase 4
43 GABA Modulators Phase 4
44 Psychotropic Drugs Phase 4
45 Narcotics Phase 4
46 Mineralocorticoids Phase 4
47 Mineralocorticoid Receptor Antagonists Phase 4
48 diuretics Phase 4
49 Diuretics, Potassium Sparing Phase 4
50 carnitine Phase 4
51 Respiratory System Agents Phase 4
52 Pulmonary Surfactants Phase 4
53 glucocorticoids Phase 4
54 Hormones Phase 4
55 Hormone Antagonists Phase 4
56 Anti-Asthmatic Agents Phase 4
57 Anti-Inflammatory Agents Phase 4
58 Bronchodilator Agents Phase 4
59
Calcium Nutraceutical Phase 4 7440-70-2 271
60
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
61
Ketoconazole Approved, Investigational Phase 3 65277-42-1 47576
62
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
63
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
64
Streptokinase Approved, Investigational Phase 3 9002-01-1
65
Nitrous oxide Approved, Vet_approved Phase 3 10024-97-2 948
66
Hydroxychloroquine Approved Phase 3 118-42-3 3652
67
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 3 439-14-5 3016
68
Clarithromycin Approved Phase 3 81103-11-9 84029
69
tannic acid Approved Phase 3 1401-55-4
70
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
71
Ravulizumab Approved, Investigational Phase 3 1803171-55-2
72
Ibuprofen Approved Phase 2, Phase 3 15687-27-1 3672
73
Acetaminophen Approved Phase 2, Phase 3 103-90-2 1983
74
Calfactant Approved Phase 3 183325-78-2
75
Nitric Oxide Approved Phase 3 10102-43-9 145068
76
Morphine Approved, Investigational Phase 2, Phase 3 57-27-2 5288826
77
Interferon beta-1a Approved, Investigational Phase 3 145258-61-3 6438354
78
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067
79 Anesthetics Phase 3
80 Anesthetics, General Phase 3
81 Analgesics Phase 3
82 Analgesics, Non-Narcotic Phase 3
83 Thyrotropin-Releasing Hormone Phase 3
84 calcium heparin Phase 3
85 Anticoagulants Phase 3
86
Beclomethasone Phase 3 4419-39-0 20469
87 Antifungal Agents Phase 3
88 Antibodies Phase 3
89 Immunoglobulins Phase 3
90 Antiprotozoal Agents Phase 3
91 Antiparasitic Agents Phase 3
92 Antimalarials Phase 3
93 Plasma-lyte 148 Phase 3
94 Immunoglobulins, Intravenous Phase 3
95 Soy Bean Phase 3
96 Betamethasone Valerate Phase 3 2152-44-5
97 Betamethasone benzoate Phase 3
98 Betamethasone-17,21-dipropionate Phase 3
99 Betamethasone sodium phosphate Phase 3
100 Betamethasone acetate Phase 3
101 Anti-Bacterial Agents Phase 3
102 Cytochrome P-450 Enzyme Inhibitors Phase 3
103 Cytochrome P-450 CYP3A Inhibitors Phase 3
104 Nutrients Phase 3
105 Vitamins Phase 3
106 Trace Elements Phase 3
107 Micronutrients Phase 3
108 Vasoactive intestinal peptide Phase 2, Phase 3 40077-57-4
109 Antibodies, Monoclonal Phase 3
110 Neuromuscular Blocking Agents Phase 3
111 Complement System Proteins Phase 3
112 Immunosuppressive Agents Phase 3
113 Antioxidants Phase 3
114 Endothelium-Dependent Relaxing Factors Phase 3
115 Vasodilator Agents Phase 3
116 Protective Agents Phase 3
117 Pharmaceutical Solutions Phase 2, Phase 3
118 Immunologic Factors Phase 3
119 Anti-Infective Agents Phase 3
120 Antiviral Agents Phase 3
121 Interferon-beta Phase 3
122 interferons Phase 3
123 Adrenergic beta-Agonists Phase 2, Phase 3
124 Adjuvants, Immunologic Phase 3
125 Hydroxyethyl Starch Derivatives Phase 3
126 Plasma Substitutes Phase 3
127 Blood Substitutes Phase 3
128 Albuterol Phase 2, Phase 3
129 Tocolytic Agents Phase 2, Phase 3
130 Omega 3 Fatty Acid Phase 3
131 Liver Extracts Phase 3
132
Evening primrose oil Investigational, Nutraceutical Phase 3 308064-97-3
133
Etanercept Approved, Investigational Phase 1, Phase 2 185243-69-0
134 Ginger Approved Phase 2
135 Coconut Approved Phase 2
136
Valganciclovir Approved, Investigational Phase 2 175865-60-8 64147
137
Ganciclovir Approved, Investigational Phase 2 82410-32-0 3454
138
Ambroxol Approved, Investigational Phase 2 18683-91-5
139
Losartan Approved Phase 2 114798-26-4 3961
140
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
141
Cisatracurium Approved Phase 2 96946-41-7
142
Atracurium Approved, Experimental, Investigational Phase 2 64228-79-1 47319
143
Naltrexone Approved, Investigational, Vet_approved Phase 2 16590-41-3 5360515
144
Ethanol Approved Phase 2 64-17-5 702
145
Carbon monoxide Approved, Investigational Phase 2 630-08-0 281
146
Hydrogen peroxide Approved, Vet_approved Phase 1, Phase 2 7722-84-1 784